Pricing Log in Create free account

Coherus Oncology, Inc. (CHRS) vs Unicycive Therapeutics, Inc. (UNCY)

Coherus Oncology, Inc. and Unicycive Therapeutics, Inc. are both Biotechnology companies. Unicycive Therapeutics, Inc. is the larger, with a market value of $105.3M against $90.0M — 1.2× the size. Unicycive Therapeutics, Inc. has the higher net margin (0.00% vs −253.4%) and the higher return on invested capital (0.00% vs 0.00%). Across the 14 metrics below, Unicycive Therapeutics, Inc. leads on 9 and Coherus Oncology, Inc. on 5.

Valuation

Metric CHRS UNCY Biotechnology median
P/E n/m n/m 11.58
P/S 1.70 n/m 9.61
P/B 3.62 1.91 2.26
Price to free cash flow n/m n/m 26.41
EV/EBITDA n/m n/m 0.72
EV/Sales 4.39 n/m 9.43
Earnings yield (165.05%) (42.76%) (32.28%)
Free cash flow yield (191.02%) (27.44%) (22.27%)

Profitability

Metric CHRS UNCY Biotechnology median
Gross margin 69.81% 0.00% 68.81%
Operating margin (275.94%) 0.00% 0.00%
Net margin (253.43%) 0.00% 0.00%
Free cash flow margin (323.85%) 0.00% 0.00%
Return on equity (240.54%) (101.07%) (50.30%)
Return on assets (39.54%) (69.05%) (45.47%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric CHRS UNCY Biotechnology median
Revenue growth (TTM) 44.36% — 6.78%
EPS growth (last fiscal year) 472.00% 70.18% 29.88%
Revenue growth, 5-year CAGR (38.41%) — 9.75%
Net income growth, 5-year CAGR 4.91% 0.00% 0.00%

Health

Metric CHRS UNCY Biotechnology median
Debt to equity 2.08 0.00 0.00
Current ratio 1.51 3.81 4.74
Net debt to EBITDA 0.76 1.43 1.01

Dividend

Metric CHRS UNCY Biotechnology median
Dividend yield — — 0.39%
Payout ratio — — —

Size

Metric CHRS UNCY Biotechnology median
Market cap 90.02m 105.29m 168.63m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack